Διαχείριση και Αναστροφή της Αντιπηξίας

Reversal of antithrombotic agents. (ανοίγει νέο παράθυρο)

Bauer KA.

Πηγή‎: Am J Hematol 2012;87 Suppl 1:S119-26.

Καταχώριση‎: PubMed 22460529

DOI‎: 10.1002/ajh.23165

https://www.ncbi.nlm.nih.gov/pubmed/22460529 (ανοίγει νέο παράθυρο)

Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. (ανοίγει νέο παράθυρο)

Chai-Adisaksopha C, Hillis C, Lim W, Boonyawat K, Moffat K, Crowther M

Πηγή‎: J Thromb Haemost 2015;13(10):1790-8.

Καταχώριση‎: PubMed 26270886

DOI‎: 10.1111/jth.13117

https://www.ncbi.nlm.nih.gov/pubmed/26270886 (ανοίγει νέο παράθυρο)

Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. (ανοίγει νέο παράθυρο)

Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, Yue P, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Demchuk AM, Pallin DJ, Concha M, Goodman S, Leeds J, Souza S, Siegal DM, Zotova E, Meeks B, Ahmad S, Nakamya J, Milling TJ Jr; ANNEXA-4 Investigators

Πηγή‎: N Engl J Med 2019;380(14):1326-35.

Καταχώριση‎: PubMed 30730782

DOI‎: 10.1056/NEJMoa1814051

https://www.ncbi.nlm.nih.gov/pubmed/30730782 (ανοίγει νέο παράθυρο)

Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. (ανοίγει νέο παράθυρο)

Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M; ANNEXA-4 Investigators

Πηγή‎: N Engl J Med 2016;375(12):1131-41.

Καταχώριση‎: PubMed 27573206

DOI‎: 10.1056/NEJMoa1607887

https://www.ncbi.nlm.nih.gov/pubmed/27573206 (ανοίγει νέο παράθυρο)

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. (ανοίγει νέο παράθυρο)

Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M

Πηγή‎: Circulation 2011;124(14):1573-9.

Καταχώριση‎: PubMed 21900088

DOI‎: 10.1161/CIRCULATIONAHA.111.029017

https://www.ncbi.nlm.nih.gov/pubmed/21900088 (ανοίγει νέο παράθυρο)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (ανοίγει νέο παράθυρο)

Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, Sarode R.

Πηγή‎: Lancet 2015;385(9982):2077-87.

Καταχώριση‎: PubMed 25728933

DOI‎: 10.1016/S0140-6736(14)61685-8

https://www.ncbi.nlm.nih.gov/pubmed/25728933 (ανοίγει νέο παράθυρο)

Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. (ανοίγει νέο παράθυρο)

Gordon JL, Fabian TC, Lee MD, Dugdale M

Πηγή‎: J Trauma Acute Care Surg 2013;75(3):475-86.

Καταχώριση‎: PubMed 24089118

DOI‎: 10.1097/TA.0b013e3182a07391

https://www.ncbi.nlm.nih.gov/pubmed/24089118 (ανοίγει νέο παράθυρο)

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. (ανοίγει νέο παράθυρο)

Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, Ortel TL, Van Cott EM, Ansell J.

Πηγή‎: Am J Hematol 2012;87 Suppl 1:S141-5.

Καταχώριση‎: PubMed 22473649

DOI‎: 10.1002/ajh.23202

https://www.ncbi.nlm.nih.gov/pubmed/22473649 (ανοίγει νέο παράθυρο)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (ανοίγει νέο παράθυρο)

Levi M, Eerenberg E, Kamphuisen PW.

Πηγή‎: J Thromb Haemost 2011;9(9):1705-12.

Καταχώριση‎: PubMed 21729240

DOI‎: 10.1111/j.1538-7836.2011.04432.x

https://www.ncbi.nlm.nih.gov/pubmed/21729240 (ανοίγει νέο παράθυρο)

Emergency reversal of warfarin anticoagulation. (ανοίγει νέο παράθυρο)

Lin Y, Callum J.

Πηγή‎: CMAJ 2010;182(18):2004.

Καταχώριση‎: PubMed 21078740

DOI‎: 10.1503/cmaj.100983

https://www.ncbi.nlm.nih.gov/pubmed/21078740 (ανοίγει νέο παράθυρο)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (ανοίγει νέο παράθυρο)

Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G.

Πηγή‎: Thromb Haemost 2012;108(2):217-24.

Καταχώριση‎: PubMed 22627883

DOI‎: 10.1160/TH12-03-0179

https://www.ncbi.nlm.nih.gov/pubmed/22627883 (ανοίγει νέο παράθυρο)

Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. (ανοίγει νέο παράθυρο)

Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H; Beriplex P/N Anticoagulation Reversal Study Group.

Πηγή‎: J Thromb Haemost 2008;6(4):622-31.

Καταχώριση‎: PubMed 18208533

DOI‎: 10.1111/j.1538-7836.2008.02904.x

https://www.ncbi.nlm.nih.gov/pubmed/18208533 (ανοίγει νέο παράθυρο)

Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. (ανοίγει νέο παράθυρο)

Piran S, Khatib R, Schulman S, Majeed A, Holbrook A, Witt DM, Wiercioch W, Schünemann HJ, Nieuwlaat R

Πηγή‎: Blood Adv 2019;3(2):158-67.

Καταχώριση‎: PubMed 30658963

DOI‎: 10.1182/bloodadvances.2018024133

https://www.ncbi.nlm.nih.gov/pubmed/30658963 (ανοίγει νέο παράθυρο)

Idarucizumab for dabigatran reversal. (ανοίγει νέο παράθυρο)

Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI.

Πηγή‎: N Engl J Med 2015;373(6):511-20.

Καταχώριση‎: PubMed 26095746

DOI‎: 10.1056/NEJMoa1502000

https://www.ncbi.nlm.nih.gov/pubmed/26095746 (ανοίγει νέο παράθυρο)

Idarucizumab for dabigatran reversal - full cohort analysis. (ανοίγει νέο παράθυρο)

Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI

Πηγή‎: N Engl J Med 2017;377(5):431-41.

Καταχώριση‎: PubMed 28693366

DOI‎: 10.1056/NEJMoa1707278

https://www.ncbi.nlm.nih.gov/pubmed/28693366 (ανοίγει νέο παράθυρο)

Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. (ανοίγει νέο παράθυρο)

Reiter RA, Mayr F, Blazicek H, Galehr E, Jilma-Stohlawetz P, Domanovits H, Jilma B

Πηγή‎: Blood 2003;102(13):4594-9.

Καταχώριση‎: PubMed 12920042

DOI‎: 10.1182/blood-2002-11-3566

https://www.ncbi.nlm.nih.gov/pubmed/12920042 (ανοίγει νέο παράθυρο)

Role of agents for reversing the effects of target-specific oral anticoagulants. (ανοίγει νέο παράθυρο)

Riley TR, Gauthier-Lewis ML, Sanchez CK, Douglas JS

Πηγή‎: Am J Health Syst Pharm 2017;74(2):54-61.

Καταχώριση‎: PubMed 27895055

DOI‎: 10.2146/ajhp150810

https://www.ncbi.nlm.nih.gov/pubmed/27895055 (ανοίγει νέο παράθυρο)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (ανοίγει νέο παράθυρο)

Skolnick BE, Shenouda M, Khutoryansky NM, Pusateri AE, Gabriel D, Carr ME.

Πηγή‎: Anesth Analg 2011;113(4):703-10.

Καταχώριση‎: PubMed 21890888

DOI‎: 10.1213/ANE.0b013e318228c690

https://www.ncbi.nlm.nih.gov/pubmed/21890888 (ανοίγει νέο παράθυρο)

2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. (ανοίγει νέο παράθυρο)

Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, Florido R, Hucker W, Mehran R, Messé SR, Pollack CV Jr, Rodriguez F, Sarode R, Siegal D, Wiggins BS

Πηγή‎: J Am Coll Cardiol 2017;70(24):3042-67.

Καταχώριση‎: PubMed 29203195

DOI‎: 10.1016/j.jacc.2017.09.1085

https://www.ncbi.nlm.nih.gov/pubmed/29203195 (ανοίγει νέο παράθυρο)

Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. (ανοίγει νέο παράθυρο)

Woo CH, Patel N, Conell C, Rao VA, Faigeles BS, Patel MC, Pombra J, Akins PT, Axelrod YK, Ge IY, Sheridan WF, Flint AC.

Πηγή‎: World Neurosurg 2014;81(1):110-5.

Καταχώριση‎: PubMed 23220122

DOI‎: 10.1016/j.wneu.2012.12.002

https://www.ncbi.nlm.nih.gov/pubmed/23220122 (ανοίγει νέο παράθυρο)

Reversal of warfarin-induced hemorrhage in the emergency department. (ανοίγει νέο παράθυρο)

Zareh M, Davis A, Henderson S.

Πηγή‎: West J Emerg Med 2011;12(4):386-92.

Καταχώριση‎: PubMed 22224125

DOI‎: 10.5811/westjem.2011.3.2051

https://www.ncbi.nlm.nih.gov/pubmed/22224125 (ανοίγει νέο παράθυρο)

ΕΠΕΊΓΟΥΣΑ ΚΑΙ ΕΝΤΑΤΙΚΉ ΘΕΡΑΠΕΊΑ

Διαχείριση και Αναστροφή της Αντιπηξίας

Ελληνική

Διαχείριση και Αναστροφή της Αντιπηξίας

https://assetsnffrgf-a.akamaihd.net/assets/ct/d8f8c0370e/images/syn_placeholder_sqr.png

Reversal of antithrombotic agents. (ανοίγει νέο παράθυρο)

Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. (ανοίγει νέο παράθυρο)

Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. (ανοίγει νέο παράθυρο)

Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. (ανοίγει νέο παράθυρο)

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. (ανοίγει νέο παράθυρο)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (ανοίγει νέο παράθυρο)

Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. (ανοίγει νέο παράθυρο)

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. (ανοίγει νέο παράθυρο)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (ανοίγει νέο παράθυρο)

Emergency reversal of warfarin anticoagulation. (ανοίγει νέο παράθυρο)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (ανοίγει νέο παράθυρο)

Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. (ανοίγει νέο παράθυρο)

Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. (ανοίγει νέο παράθυρο)

Idarucizumab for dabigatran reversal. (ανοίγει νέο παράθυρο)

Idarucizumab for dabigatran reversal - full cohort analysis. (ανοίγει νέο παράθυρο)

Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. (ανοίγει νέο παράθυρο)

Role of agents for reversing the effects of target-specific oral anticoagulants. (ανοίγει νέο παράθυρο)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (ανοίγει νέο παράθυρο)

2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. (ανοίγει νέο παράθυρο)

Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. (ανοίγει νέο παράθυρο)

Reversal of warfarin-induced hemorrhage in the emergency department. (ανοίγει νέο παράθυρο)

Επικοινωνία με Τοπικό Εκπρόσωπο της Επιτροπής Προσέγγισης Νοσοκομείων

Ενημερωτικό Υλικό για τον Ιατρικό Κλάδο

Βίντεο

Διαχείριση και Αναστροφή της Αντιπηξίας

Επιλέξτε τη Γλώσσα Σας

Κοινή χρήση